Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus ZYRTEC.
HISTAFED vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine